Tag Archives: CTLT

Top Casino Stocks To Own Right Now

High-yield stocks can give income portfolios a nice boost, but not every high-yield stock deserves a spot in your income portfolio. Sometimes, a high yield can indicate business problems that cause share prices to fall, and when that happens, the losses can far exceed any benefit associated with pocketing dividend checks.

You won’t always be able to avoid that risk, but taking the time to consider the business behind the high yield before buying may reduce your risk. For instance,Hess Midstream Partners (NYSE:HESM), Signet Jewelers Ltd (NYSE:SIG), and Enbridge, Inc. (NYSE:ENB) are high-yielding stocks that are backed by strong businesses, which could make them worth owning.

Drillers aren’t the only ones benefiting from U.S. shale

Todd Campbell (Hess Midstream Partners): In April 2017, Hess Corp.(NYSE:HES) spun off various midstream infrastructure in the Bakken shale as a new master limited partnership: Hess Midstream Partners. Since then,Hess Midstream Partners’ share price has declined about 20%, which makes it an intriguing stock for income investors to buy.

Top Casino Stocks To Own Right Now: Harmony Gold Mining Company Limited(HMY)

Harmony Gold Mining Company Limited engages in the exploration and mining of gold in South Africa and Papua New Guinea. The company also explores for copper, silver, uranium, and molybdenum deposits. It has nine underground operations located on the Witwatersrand Basin; an open-pit mine exploiting the Kraaipan Greenstone Belt; and various other surface operations in South Africa. The company also owns a 50% interest in the Hidden Valley, an open-pit gold and silver mine; the Wafi-Golpu project; and exploration tenements in Papua New Guinea. Harmony Gold Mining Company Limited was incorporated in 1950 and is based in Randfontein, South Africa.

Advisors’ Opinion:


    For the details of Exor Investments (UK) LLP’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Exor+Investments+%28UK%29+LLP

    These are the top 5 holdings of Exor Investments (UK) LLPSibanye-Stillwater (SBGL) – 45,970,311 shares, 32.51% of the total portfolio. Shares added by 8.09%VEON Ltd (VEON) – 37,657,792 shares, 31.02% of the total portfolio. Shares added by 3.83%Cameco Corp (CCJ) – 5,967,410 shares, 19.32% of the total portfolio. Harmony Gold Mining Co Ltd (HMY) – 13,275,728 shares, 6.26% of the total portfolio. Shares added by 6.84%Novagold Resources Inc (NG) – 5,889,905 shares, 6.21% of the total portfolio. Shares

  • [By Paul Ausick]

    Harmony Gold Mining Co. Ltd. (NYSE: HMY) has a market cap of around $1 billion and traded this morning at $1.90, in a 52-week range of $1.43 to $2.53. Shares are down 4.1% for the past 12 months, and the company posted an operating loss of around $265,000. The company is based in South Africa and owns assets in South Africa and Papua New Guinea.

Top Casino Stocks To Own Right Now: Galapagos NV(GLPG)

Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The company is developing filgotinib, which has completed Phase 2 clinical trial for the treatment of rheumatoid arthritis and Crohns disease; GLPG1837, which is in Phase 2 clinical program, as well as GLPG2222, which is in Phase 1 clinical trial for treatment of cystic fibrosis mutations; and GLPG1690, which has completed Phase 1 clinical trial for the treatment of idiopathic pulmonary fibrosis. It is also developing GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; MOR106, which is in pre-clinical stage for the treatment of inflammatory diseases; and GLPG2665, a pre-clinical candidate for cystic fibrosis. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; and with Servier to develop GLPG1972. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Advisors’ Opinion:

  • [By Brian Feroldi, Chuck Saletta, and Todd Campbell]

    But which biotech stocks are worth a closer look during thisrecent rally?We asked three Motley Fool contributors to weigh in, and they pickedGalapagos (NASDAQ:GLPG), Celgene (NASDAQ:CELG), andZealand Pharma (NASDAQ:ZEAL).

  • [By Cory Renauer]

    The end of the first quarter is just a few weeks away and more than a few biotechs still haven’t delivered the important clinical trial results they told investors to expect before the end of the period. The clock’s ticking for Axsome Therapeutics (NASDAQ:AXSM), Galapagos (NASDAQ:GLPG) and their experimental treatments.

  • [By Ethan Ryder]

    Cowen restated their buy rating on shares of GALAPAGOS NV/S (NASDAQ:GLPG) in a research report sent to investors on Friday morning.

    Several other brokerages have also recently issued reports on GLPG. Zacks Investment Research raised shares of GALAPAGOS NV/S from a hold rating to a buy rating and set a $112.00 target price for the company in a report on Tuesday, October 30th. Raymond James started coverage on shares of GALAPAGOS NV/S in a report on Wednesday, November 14th. They issued a strong-buy rating and a $157.00 target price for the company. Credit Suisse Group decreased their target price on shares of GALAPAGOS NV/S from $92.00 to $90.00 and set a hold rating for the company in a report on Friday, October 26th. ValuEngine cut shares of GALAPAGOS NV/S from a strong-buy rating to a buy rating in a report on Wednesday, January 2nd. Finally, Nomura lifted their target price on shares of GALAPAGOS NV/S from $124.00 to $140.00 and gave the stock a buy rating in a report on Tuesday, October 30th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $123.64.

Top Casino Stocks To Own Right Now: Nortek Inc.(NTK)

NetScientific plc is a transatlantic healthcare technology company. The Company develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in the United States and Europe with a primary focus on diagnostics, digital health and therapeutics. The Company is engaged in the development of intellectual property. Its portfolio consists of WANDA Health, an analytics company that uses machine learning to derive a personalized risk score for Congestive Heart Failure patients; Glucosense, a provider of a non-invasive glucose monitoring wearable device; Vortex Biosciences, which is engaged in circulating tumor cell identification, selection and analysis for disease monitoring and personalized therapeutic prescribing; Glycotest, which provides non-invasive blood tests for liver cancers and fibrosis-cirrhosis, and ProAxsis, which is engaged in respiratory disease diagnosis and treatment monitoring. Advisors’ Opinion:

  • [By Shane Hupp]

    NetKoin (NTK) is a token. It was first traded on January 7th, 2018. NetKoin’s total supply is 7,853,060,094 tokens and its circulating supply is 3,976,070,194 tokens. NetKoin’s official website is www.netkoin.com. NetKoin’s official Twitter account is @netkoin and its Facebook page is accessible here.

  • [By Logan Wallace]

    Neurotoken (CURRENCY:NTK) traded down 8.5% against the dollar during the 1 day period ending at 22:00 PM Eastern on September 2nd. One Neurotoken token can currently be purchased for approximately $0.0421 or 0.00000579 BTC on cryptocurrency exchanges including BCEX, YoBit, Tidex and Cobinhood. In the last seven days, Neurotoken has traded 17.7% lower against the dollar. Neurotoken has a total market capitalization of $3.41 million and approximately $211,773.00 worth of Neurotoken was traded on exchanges in the last day.

Top Casino Stocks To Own Right Now: Celgene Corporation(CELG)

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID to treat multiple myeloma; and OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, ankylosing spondylitis, Beh莽et’s disease, atopic dermatitis, and ulcerative colitis. The companys products also include VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); THALOMID for the patients with multiple myeloma and erythema nodosum leprosum; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN products. Its clinical stage products include OTEZLA for the treatment of various immune-inflammatory diseases; sotatercept for the treatment of renal anemia, beta-thalassemia and MDS; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; PDA-002 for the treat diabetic foot ulcers and peripheral neuropathy; and PNK-007 for hematological malignancies treatment. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; and Triphase Accelerator Corporation, as well as a strategic collaboration with Nurix, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Advisors’ Opinion:

  • [By Ethan Ryder]

    Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.32 by $0.07. Celgene had a net margin of 26.48% and a return on equity of 114.66%. The business had revenue of $4.04 billion for the quarter, compared to analyst estimates of $3.98 billion. During the same quarter in the previous year, the business earned $2.00 earnings per share. Equities research analysts anticipate that Celgene Co. will post 10.01 EPS for the current fiscal year.

    ILLEGAL ACTIVITY WARNING: “Bank of The West Boosts Stake in Celgene Co. (CELG)” was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at www.tickerreport.com/banking-finance/4282863/bank-of-the-west-boosts-stake-in-celgene-co-celg.html.

    About Celgene

  • [By ]

    Bristol-Myers Squibb (NYSE: BMY), one of the largest U.S. pharma companies by revenue, didn’t waste any time scooping up biotech Celgene (Nasdaq: CELG). Announced on January 3, the $74 billion acquisition is the second-largest pharmaceutical M&A deal ever (after the $87 billion merger of Warner-Lambert and Pfizer (NYSE: PFE) twenty years ago).

Top Casino Stocks To Own Right Now: Catalent, Inc.(CTLT)

Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products worldwide. It operates through three segments: Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development, and manufacturing of oral dose forms for prescription and consumer health products. This segments oral dose forms include soft gel, modified release technologies, and immediate release solid oral products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development & Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also offers analytical chemical and cell-based testing and scientific services, stability testing, respiratory products formulation and manufacturing, regulatory consulting, and bioanalytical testing for biologic products. The company serves large pharmaceutical and biotechnology companies; mid-size, emerging, and specialty pharmaceutical and biotechnology companies; and consumer health companies, as well as companies in other healthcare market segments, such as animal health and medical devices and companies in industries, including cosmetics. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Catalent (CTLT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Catalent (CTLT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top Casino Stocks To Own Right Now: Simmons First National Corporation(SFNC)

Simmons First National Corporation (the “Company”) is a financial holding company registered under the Bank Holding Company Act of 1956, as amended. The Company is headquartered in Arkansas with total assets of $7.6 billion, loans of $4.9 billion, deposits of $6.1 billion and equity capital of $1.1 billion as of December 31, 2015. We conduct banking operations through 149 branches, or “financial centers,” located in communities throughout Arkansas, Kansas, Missouri and Tennessee.

We seek to build shareholder value by (i) focusing on strong asset quality, (ii) maintaining strong capital (iii) managing our liquidity position, (iv) improving our operational efficiency (v) opportunistically growing our business, both organically and through acquisitions of financial institutions.

Subsidiary Bank

Our subsidiary bank, Simmons First National Bank (“Simmons Bank” or “lead bank”), is a national bank which has been in operation since 1903.   Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Simmons First National (SFNC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Allred Capital Management LLC purchased a new position in shares of Simmons First National Co. (NASDAQ:SFNC) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 13,770 shares of the bank’s stock, valued at approximately $332,000.